Key takeaways:
- Fosun Pharma’s revenue and profit both rose around 30% last year as Covid-19 vaccines and stake sales in its subsidiaries contributed to its top and bottom lines
- The company’s gross margin fell sharply as some of its drugs were added to government procurement programs that promise higher sales but at heavy discounts
